Los Angeles Capital Management
JNCE

Los Angeles Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Los Angeles Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-92,420
Closed -$638K – 1552
2020
Q2 		$638K Buy
92,420
+39,494
+75% +$213K ﹤0.01% 1018
2020
Q1 		$251K Buy
+52,926
New +$305K ﹤0.01% 1115

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Los Angeles Capital Management's JNCE Position: Q3 2020 in Review

Los Angeles Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2020, closing a stake of 92,420 shares — an estimated $638K sold.

Los Angeles Capital Management first reported a position in JNCE in Q1 2020 and held it in 2 quarters. The position peaked at $638K in Q2 2020. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2020.

  • Los Angeles Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Los Angeles Capital Management sold 92,420 Jounce Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $638K.
  • Los Angeles Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2020 and held it in 2 quarters.
  • Los Angeles Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $638K in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Los Angeles Capital Management's 13F filing for Q3 2020, filed 2 Nov 2020.